Measuring Within-Individual Cannabis Reduction in Clinical Trials: a Review of the Methodological Challenges
Purpose of Review
Cannabis abstinence, traditionally, is the primary outcome in cannabis use disorder (CUD) treatment trials. Due to the changing legality of cannabis, patient goals, and preliminary evidence suggesting that individuals who reduce their cannabis use may show functional improvements, cannabis reduction is a desirable alternative outcome in CUD trials. We review challenges in measuring cannabis reduction and the evidence to support various definitions of reduction.
Reduction in number of cannabis use days was associated with improvements in functioning across several studies. Reductions in quantity of cannabis used was inconsistently associated with improvements in functioning, though definitions of quantity varied across studies. Different biomarkers may be used depending on the reduction outcome.
Biologically confirmed reductions in frequency of cannabis use days may represent a viable endpoint in clinical trials for cannabis use disorder. Additional research is needed to better quantify reduction in cannabis amounts.
KeywordsCannabis use disorder Harm reduction Cannabis quantification Randomized controlled trial Biomarkers Δ9-tetrahydrocannabinol
Effort was supported by National Institutes of Health grants from the National Institute of Drug Abuse (R01 DA042114), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12 HD055885), and the National Institute on Alcohol Abuse and Alcoholism (K23 AA025399).
Compliance with Ethical Standards
Conflict of Interest
Marilyn A. Huestis provides consultation to Pinney & Associates, Inc., Canopy Health Innovations, Intelligent Fingerprinting, Cannabix, Evanostics, Inc., and the Center for Forensic Science Research and Education. Kevin M. Gray provides consultation to Pfizer, Inc.
Human and Animal Rights and Informed Consent
This article does not contain any original studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th edition, text revision): Washington,D,C.,American Psychiatric Pub; 2000.Google Scholar
- 3.Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD005336. https://doi.org/10.1002/14651858.CD005336.pub4
- 4.Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD008940. https://doi.org/10.1002/14651858.CD008940.pub3.
- 9.•• Lee DC, Schlienz NJ, Peters EN, Dworkin RH, Turk DC, Strain EC, et al. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. Drug Alcohol Depend. 2019;194:500–17 This systematic review describes primary and secondary outcome measures typically assessed in psychosocial and pharmacotherapy clinical trials for cannabis use disorder. PubMedCrossRefPubMedCentralGoogle Scholar
- 11.•• Loflin MJE, Huestis MA, Aklin, WM, Budney AJ, D’Souza DC, Dworkin RH, Gray KM, Kiluk BD, Lee D, Le Foll B, Lile JA, Mason BJ, McRae-Clark AL, Montoya I, Peters EN, Ramey T, Turk DC, Vandrey R, Weiss RD, Strain EC. Choosing clinical endpoints for cannabis use disorder clinical trials: ACTTION meeting recommendations. Under Review. This manuscript reviews recommendations from experts in cannabis use disorder with regard to the assessment of cannabis use in clinical trials. Google Scholar
- 12.Riggs NR, Conner BT, Parnes JE, Prince MA, Shillington AM, George MW. Marijuana eCHECKUPTO GO: Effects of a personalized feedback plus protective behavioral strategies intervention for heavy marijuana-using college students. Drug Alcohol Depend. 2018;190:13–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 13.Food and Drug Administration. Alcoholism: developing drugs for treatment (No FDA D-0152-001) Silver Spring. https://www.fda.gov/files/drugs/published/Alcoholism---Developing-Drugs-for-Treatment.pdf
- 34.• Fitzmaurice GM, Lipsitz SR, Weiss RD. Statistical considerations in the choice of endpoint for drug use disorder trials. Drug Alcohol Depend. 2017;181:219–22 This manuscript illustrates statistical and power considerations when choosing an outcome measure in substance use disorder clinical trials. PubMedPubMedCentralCrossRefGoogle Scholar
- 44.Hindocha C, Freeman TP, Curran HV. Anatomy of a joint: comparing self-reported and actual dose of cannabis and tobacco in a joint, and how these are influenced by controlled acute administration. Cannabis Cannabinoid Res. 2017:2217–23.Google Scholar
- 47.Donovan DM, Bigelow GE, Brigham GS, Carroll KM, Cohen AJ, Gardin JG, et al. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction. 2012;107(4):694–708.PubMedCrossRefPubMedCentralGoogle Scholar
- 64.D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35–45.PubMedCrossRefGoogle Scholar